This study looks at how a new drug called vudalimab (also known as XmAb20717) helps people with certain advanced cancers. These cancers affect parts of the body like the ovaries, cervix, and prostate. The study has two parts. In the first part, small groups of 10 people with specific types of cancer will try the drug. If it works well, more people may join in the second part. The study is open-label, which means both the doctors and patients know they are taking the drug.

Key Points:

• The study may last for several weeks, and patients will need to visit the study center regularly.
• Patients must be at least 18 years old and have tried other treatments before joining.
• People in the study should not be using other cancer treatments while participating.

People can join if they are 18 or older, have certain types of cancer, and have tried other treatments before. Pregnant or breastfeeding women cannot participate. The study hopes to find out if the drug can help shrink tumors and improve health.